Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $200.00 short put and a strike $195.00 long put offers a potential 31.58% return on risk over the next 13 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $200.00 by expiration. The full premium credit of $1.20 would be kept by the premium seller. The risk of $3.80 would be incurred if the stock dropped below the $195.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 68.71 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Lilly to Participate in Goldman Sachs Healthcare Conference
Thu, 03 Jun 2021 14:00:00 +0000
Eli Lilly and Company (NYSE: LLY) will participate in the Goldman Sachs Healthcare Conference on June 9 and 10, 2021. Anne White, senior vice president and president, Lilly Oncology and Jake Van Naarden, CEO, Loxo Oncology at Lilly, will participate in a virtual fireside chat on Wednesday, June 9 at 8:50 a.m., Eastern Time.
Lilly Reveals Critical Barriers to Optimal Migraine Care and Insights From Novel Clinical and Patient-Centric Real-World Evidence, Supporting Lilly's Preventive and Acute Treatment Portfolio at AHS 2021
Thu, 03 Jun 2021 10:45:00 +0000
To improve the understanding and advance the treatment of migraine, Eli Lilly and Company (NYSE: LLY) presented data on unmet needs in migraine from the OVERCOME (U.S.) study and on its portfolio of migraine medicines during the American Headache Society (AHS) 2021 Virtual Annual Scientific Meeting, June 3-6. New findings from OVERCOME (U.S.) revealed the top six reasons why people hesitate to seek migraine care.1 Real-world data insights revealed greater adherence and persistence for Emgality®
Lilly's Olumiant Found to Lower Pain In Late-Stage Rheumatoid Arthritis Trial
Wed, 02 Jun 2021 16:06:40 +0000
Eli Lilly And Co (NYSE: LLY) has reported posthoc analyses data from the Phase 3 RA-BEAM study that showed Olumiant 4mg (baricitinib) lowered pain and duration of morning joint stiffness in moderate to severe rheumatoid arthritis (RA) patients. Discovered by Incyte Corporation (NASDAQ: INCY) and licensed to Lilly, Olumiant is an oral Janus kinase (JAK) inhibitor approved for treating moderately to severely active RA in adults. Trial data showed that Olumiant also enhanced overall physical functi
Thirty Madison Vaults to Unicorn Status, Raises $140 Million
Wed, 02 Jun 2021 10:00:00 +0000
(Bloomberg) — Thirty Madison, a health-care startup that specializes in treating chronic conditions, has raised $140 million in funding, valuing the company at more than $1 billion and granting it so-called unicorn status.HealthQuest Capital led the funding round, which included participation by Mousse Partners and Bracket Capital, as well existing backers Polaris Partners, Johnson & Johnson Innovation – JJDC Inc., Greycroft and Northzone.“The new funding will allow us to drive better patient e
15 Most Valuable Pharmaceutical Companies In The World
Wed, 02 Jun 2021 05:44:25 +0000
In this article we are going to list the 15 most valuable pharmaceutical companies in the world. Click to skip ahead and jump to the 5 most valuable pharmaceutical companies in the world. There is no denying the impact that the global pharma industry has had in the world, and probably been responsible for the […]
Also on Market Tamer…
Follow Us on Facebook